Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 10;8(12):e70049.
doi: 10.1002/hem3.70049. eCollection 2024 Dec.

Early progression beyond first-line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study

Alberto Bavieri  1 , Maria E Nizzoli  2   3 , Alessandra Tucci  4 , Vittorio R Zilioli  5 , Jacopo Olivieri  6 , Benedetta Bianchi  7 , Mansueto G Rosaria  8 , Ombretta Annibali  9 , Alessia Bari  10 , Gloria M Casaluci  11 , Michele Cimminiello  12 , Nicola Di Renzo  13 , Federica Cavallo  14   15 , Vicenzo Pavone  16 , Clara Mannarella  17 , Annalisa Arcari  18 , Maggi Alessandro  19 , Antonella Anastasia  4 , Vittoria Tarantino  20 , Antonino Neri  21 , Massimo Gentile  22   23 , Fortunato Morabito  24 , Stefano Luminari  2   25
Affiliations

Early progression beyond first-line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study

Alberto Bavieri et al. Hemasphere. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Survival after relapse (SAR) stratified by early progression of disease (POD) after second‐line therapy, that is, within 24 months (POD24r) or longer than 24 months (Reference group) (A), and by combining POD24 and POD24r (B). The combinations resulted in 4 groups, that is, those with neither POD24 nor POD24r (Reference group), cases with only POD24 or POD24r, and cases with both POD24 and POD24r.
See this image and copyright information in PMC

References

    1. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720‐1748. 10.1038/s41375-022-01620-2 - DOI - PMC - PubMed
    1. Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66(6):443‐459. 10.3322/caac.21357 - DOI - PubMed
    1. Tan D, Horning SJ, Hoppe RT, et al. Improvements in observed and relative survival in follicular grade 1‐2 lymphoma during 4 decades: the Stanford University experience. Blood. 2013;122(6):981‐987. 10.1182/blood-2013-03-491514 - DOI - PMC - PubMed
    1. Sarkozy C, Maurer MJ, Link BK, et al. Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts. J Clin Oncol. 2019;37(2):144‐152. 10.1200/JCO.18.00400 - DOI - PMC - PubMed
    1. Jacobsen E. Follicular lymphoma: 2023 update on diagnosis and management. Am J Hematol. 2022;97(12):1638‐1651. 10.1002/ajh.26737 - DOI - PubMed

LinkOut - more resources